Cargando…
I
Ibandronate A bisphosphonate licensed for the treatment of postmenopausal osteoporosis. The drug can be administered orally or by slow intravenous injection. Orally, it is given before meals and washed down with a cup of water; afterwards, the patient must sit and not lie down for 30 min. The oral d...
Autores principales: | Rovenský, Jozef, Payer, Juraj, Herold, Manfred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123502/ http://dx.doi.org/10.1007/978-3-319-21335-4_9 |
Ejemplares similares
-
Osteoporosis, Fractures, and Diabetes
por: Jackuliak, Peter, et al.
Publicado: (2014) -
Corrigendum to “Osteoporosis, Fractures, and Diabetes”
por: Jackuliak, Peter, et al.
Publicado: (2017) -
CYB5A polymorphism increases androgens and reduces risk of rheumatoid arthritis in women
por: Stark, Klaus, et al.
Publicado: (2015) -
Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study
por: Koller, Tomas, et al.
Publicado: (2017) -
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
por: Payer, Juraj, et al.
Publicado: (2010)